Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03595059 : A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Breast,LungBreast,Non-Small Cell Lung Cancer,Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase I study is assessing how safe and effective a new targeted therapy (ABBV-155) is alone, or in combination with chemotherapy (paclitaxel or docetaxel), in people with small cell lung cancer, non-small cell lung cancer or breast cancer.
 

This trial is treating patients with small cell lung cancer, non-small cell lung cancer and HR-positive/HER2-negative breast cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Commercial Sponsor

AbbVie

Summary

This study has two parts: Dose Escalation (Part 1) and Dose Expansion (Part 2). Part 1 is complete, and the study is now recruiting for Part 2. Part 2 has two cohorts. Cohort 2a will enrol participants with relapsed or refractory (R/R) small cell lung cancer (SCLC), and these participants will receive ABBV-155 as monotherapy (via IV). Cohort 2b will enrol both people R/R non-small cell lung cancer (NSCLC) or people with breast cancer, who will receive ABBV-155 plus a taxane (paclitaxel or docetaxel) (via IV).

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Heather Rootes
PCCTU.Breast@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next